Concepedia

Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report

Sebastian Woźniak, Małgorzata Mackiewicz-Wysocka, Łukasz Krokowicz, Łukasz Kwinta, Jacek Mackiewicz

Oncology Research and Treatment · 2015 · 24 citations · 11 references

DOI

Abstract

This AE was probably caused by antineutrophil antibodies associated with ipilimumab treatment. To our knowledge this is the first case report of febrile neutropenia in a metastatic melanoma patient treated with ipilimumab 3 mg/kg.

References

11

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 14.9K citations · Full text

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.4K citations

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day et al. · Clinical Cancer Research · 2009 · 3.2K citations

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Dirk Schadendorf, F. Stephen Hodi, Caroline Robert et al. · Journal of Clinical Oncology · 2015 · 2.1K citations · Full text

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Jedd D. Wolchok, Bart Neyns, Gerald P. Linette et al. · The Lancet Oncology · 2009 · 1.2K citations

, , +8